Prognostic factors in head and neck rhabdomyosarcoma

James H. Simon, Arnold C. Paulino, Russell B. Smith, John M. Buatti

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background. Rhabdomyosarcoma comprises less than 1% of all head and neck cancer. The purpose of our study is to review our institutional experience in this disease and to identify possible prognostic factors for patients with head and neck rhabdomyosarcoma. Methods. One hundred forty patients with rhabdomyosarcoma were identified from 1955-1999 within the tumor registry. Of these cases, 49 (35%) were noted to be primary head and neck rhabdomyosarcomas. Retrospective chart reviews were completed to obtain the following data: age, gender, site, tumor size, histologic findings, Intergroup Rhabdomyosarcoma Study Group, treatment, local control, and survival. Results. The 5-year overall survival and local control rates were 60% ± 14% and 70% ± 14%, respectively. Tumor size ≤5 cm (p = .014) and age ≤11 years (p = .036) were predictive of improved survival, whereas age ≤11 years was predictive of improved local control (p = .006). Children ≤11 years with a ≤5-cm tumor have the best overall survival, whereas patients >11 years with a tumor >5 cm have the worst survival. The 5-year survival was intermediate for children ≤11 years with a >5-cm tumor and patients >11 years with a ≤5-cm tumor. Radiotherapy treatment duration ≤45 days in group III disease was associated with improved overall survival but not local control. For the six patients with group I or II disease, who did not receive initial chemotherapy, five had relapses at the primary and/or distant sites. Conclusions. Improvement in outcome was obtained with multimodality treatment regimens for head and neck rhabdomyosarcoma. Both tumor size and age of patient were found to influence survival.

Original languageEnglish (US)
Pages (from-to)468-473
Number of pages6
JournalHead and Neck
Volume24
Issue number5
DOIs
StatePublished - May 23 2002

Fingerprint

Rhabdomyosarcoma
Neck
Head
Survival
Neoplasms
Head and Neck Neoplasms
Registries
Radiotherapy
Therapeutics
Recurrence
Drug Therapy

Keywords

  • Age
  • Chemotherapy
  • Head and neck
  • Radiotherapy
  • Rhabdomyosarcoma
  • Surgery

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Simon, J. H., Paulino, A. C., Smith, R. B., & Buatti, J. M. (2002). Prognostic factors in head and neck rhabdomyosarcoma. Head and Neck, 24(5), 468-473. https://doi.org/10.1002/hed.10070

Prognostic factors in head and neck rhabdomyosarcoma. / Simon, James H.; Paulino, Arnold C.; Smith, Russell B.; Buatti, John M.

In: Head and Neck, Vol. 24, No. 5, 23.05.2002, p. 468-473.

Research output: Contribution to journalArticle

Simon, JH, Paulino, AC, Smith, RB & Buatti, JM 2002, 'Prognostic factors in head and neck rhabdomyosarcoma', Head and Neck, vol. 24, no. 5, pp. 468-473. https://doi.org/10.1002/hed.10070
Simon JH, Paulino AC, Smith RB, Buatti JM. Prognostic factors in head and neck rhabdomyosarcoma. Head and Neck. 2002 May 23;24(5):468-473. https://doi.org/10.1002/hed.10070
Simon, James H. ; Paulino, Arnold C. ; Smith, Russell B. ; Buatti, John M. / Prognostic factors in head and neck rhabdomyosarcoma. In: Head and Neck. 2002 ; Vol. 24, No. 5. pp. 468-473.
@article{f7c17da5164147908fa1ae2aaf89030b,
title = "Prognostic factors in head and neck rhabdomyosarcoma",
abstract = "Background. Rhabdomyosarcoma comprises less than 1{\%} of all head and neck cancer. The purpose of our study is to review our institutional experience in this disease and to identify possible prognostic factors for patients with head and neck rhabdomyosarcoma. Methods. One hundred forty patients with rhabdomyosarcoma were identified from 1955-1999 within the tumor registry. Of these cases, 49 (35{\%}) were noted to be primary head and neck rhabdomyosarcomas. Retrospective chart reviews were completed to obtain the following data: age, gender, site, tumor size, histologic findings, Intergroup Rhabdomyosarcoma Study Group, treatment, local control, and survival. Results. The 5-year overall survival and local control rates were 60{\%} ± 14{\%} and 70{\%} ± 14{\%}, respectively. Tumor size ≤5 cm (p = .014) and age ≤11 years (p = .036) were predictive of improved survival, whereas age ≤11 years was predictive of improved local control (p = .006). Children ≤11 years with a ≤5-cm tumor have the best overall survival, whereas patients >11 years with a tumor >5 cm have the worst survival. The 5-year survival was intermediate for children ≤11 years with a >5-cm tumor and patients >11 years with a ≤5-cm tumor. Radiotherapy treatment duration ≤45 days in group III disease was associated with improved overall survival but not local control. For the six patients with group I or II disease, who did not receive initial chemotherapy, five had relapses at the primary and/or distant sites. Conclusions. Improvement in outcome was obtained with multimodality treatment regimens for head and neck rhabdomyosarcoma. Both tumor size and age of patient were found to influence survival.",
keywords = "Age, Chemotherapy, Head and neck, Radiotherapy, Rhabdomyosarcoma, Surgery",
author = "Simon, {James H.} and Paulino, {Arnold C.} and Smith, {Russell B.} and Buatti, {John M.}",
year = "2002",
month = "5",
day = "23",
doi = "10.1002/hed.10070",
language = "English (US)",
volume = "24",
pages = "468--473",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic factors in head and neck rhabdomyosarcoma

AU - Simon, James H.

AU - Paulino, Arnold C.

AU - Smith, Russell B.

AU - Buatti, John M.

PY - 2002/5/23

Y1 - 2002/5/23

N2 - Background. Rhabdomyosarcoma comprises less than 1% of all head and neck cancer. The purpose of our study is to review our institutional experience in this disease and to identify possible prognostic factors for patients with head and neck rhabdomyosarcoma. Methods. One hundred forty patients with rhabdomyosarcoma were identified from 1955-1999 within the tumor registry. Of these cases, 49 (35%) were noted to be primary head and neck rhabdomyosarcomas. Retrospective chart reviews were completed to obtain the following data: age, gender, site, tumor size, histologic findings, Intergroup Rhabdomyosarcoma Study Group, treatment, local control, and survival. Results. The 5-year overall survival and local control rates were 60% ± 14% and 70% ± 14%, respectively. Tumor size ≤5 cm (p = .014) and age ≤11 years (p = .036) were predictive of improved survival, whereas age ≤11 years was predictive of improved local control (p = .006). Children ≤11 years with a ≤5-cm tumor have the best overall survival, whereas patients >11 years with a tumor >5 cm have the worst survival. The 5-year survival was intermediate for children ≤11 years with a >5-cm tumor and patients >11 years with a ≤5-cm tumor. Radiotherapy treatment duration ≤45 days in group III disease was associated with improved overall survival but not local control. For the six patients with group I or II disease, who did not receive initial chemotherapy, five had relapses at the primary and/or distant sites. Conclusions. Improvement in outcome was obtained with multimodality treatment regimens for head and neck rhabdomyosarcoma. Both tumor size and age of patient were found to influence survival.

AB - Background. Rhabdomyosarcoma comprises less than 1% of all head and neck cancer. The purpose of our study is to review our institutional experience in this disease and to identify possible prognostic factors for patients with head and neck rhabdomyosarcoma. Methods. One hundred forty patients with rhabdomyosarcoma were identified from 1955-1999 within the tumor registry. Of these cases, 49 (35%) were noted to be primary head and neck rhabdomyosarcomas. Retrospective chart reviews were completed to obtain the following data: age, gender, site, tumor size, histologic findings, Intergroup Rhabdomyosarcoma Study Group, treatment, local control, and survival. Results. The 5-year overall survival and local control rates were 60% ± 14% and 70% ± 14%, respectively. Tumor size ≤5 cm (p = .014) and age ≤11 years (p = .036) were predictive of improved survival, whereas age ≤11 years was predictive of improved local control (p = .006). Children ≤11 years with a ≤5-cm tumor have the best overall survival, whereas patients >11 years with a tumor >5 cm have the worst survival. The 5-year survival was intermediate for children ≤11 years with a >5-cm tumor and patients >11 years with a ≤5-cm tumor. Radiotherapy treatment duration ≤45 days in group III disease was associated with improved overall survival but not local control. For the six patients with group I or II disease, who did not receive initial chemotherapy, five had relapses at the primary and/or distant sites. Conclusions. Improvement in outcome was obtained with multimodality treatment regimens for head and neck rhabdomyosarcoma. Both tumor size and age of patient were found to influence survival.

KW - Age

KW - Chemotherapy

KW - Head and neck

KW - Radiotherapy

KW - Rhabdomyosarcoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0036250808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036250808&partnerID=8YFLogxK

U2 - 10.1002/hed.10070

DO - 10.1002/hed.10070

M3 - Article

C2 - 12001077

AN - SCOPUS:0036250808

VL - 24

SP - 468

EP - 473

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 5

ER -